Michael R. Bishop to Lymphocyte Transfusion
This is a "connection" page, showing publications Michael R. Bishop has written about Lymphocyte Transfusion.
Connection Strength
1.294
-
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11; 121(15):2864-74.
Score: 0.452
-
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1022-30.
Score: 0.307
-
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol. 2004 Feb; 31(1):37-46.
Score: 0.241
-
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12; 122(25):4129-39.
Score: 0.118
-
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S138-45.
Score: 0.090
-
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol. 2004 Sep; 126(6):837-43.
Score: 0.063
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
Score: 0.024